Comparative Pharmacology
Head-to-head clinical analysis: DEXEDRINE versus FOCALIN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXEDRINE versus FOCALIN XR.
DEXEDRINE vs FOCALIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.
Focalin XR (dexmethylphenidate) is a central nervous system stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft. The d-threo enantiomer is pharmacologically active.
5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.
Initial 20 mg orally once daily; may increase in 10-20 mg increments at weekly intervals; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours for dextroamphetamine; clinical effects last longer due to CNS accumulation
Terminal half-life: 2-3 hours for immediate-release; 6-8 hours for extended-release (FOCALIN XR)
Renal: 30-45% unchanged, 50-60% as deaminated metabolites; fecal: minor (<5%)
Renal (approximately 90% as unchanged drug and metabolites)
Category C
Category C
CNS Stimulant
CNS Stimulant